Katy Perry has revealed that �??Vicky Cristina Barcelona�?? star Scarlett Johansson was the inspiration behind her smash reach �??I Kissed A Girl�??.
Perry says she was flicking through a magazine when she came across a picture of Johansson, and told her boyfriend she would �??make out�?? with the actress,
"'I Kissed a Girl' was divine when I opened up a magazine and I saw a picture of Scarlett Johansson�?� Perry told Steppin�?? Out magazine. "I was with my beau at the time, and I said to him, 'I�??m not going to lie: If Scarlett Johansson walked into the room and wanted to create out with me, I would give out with her. I hope you�??re oK with that?'"
Perry�??s current fellow is Gym Class Heroes singer Travis McCoy.
Meanwhile, Kanye West likewise recently told the world of his appreciation for Johansson, blogging that she�??s his �??deary white girl�?�.
--By our New York staff.
Find out more about NME.
More information
Thursday, 4 September 2008
Friday, 15 August 2008
BioMS Medical Announces Positive Interim Analysis On Phase III Trial Of Dirucotide (MBP8298) For Multiple Sclerosis
�BioMS Medical Corp. (TSX:
MS), a leading developer in the treatment of multiple sclerosis (MS),
proclaimed that the independent Drug Safety Monitoring Board (DSMB) for the
MAESTRO-01 trial has conducted the scheduled interim analysis of efficacy
and safety and has recommended that the tryout continue to completion.
MAESTRO-01 is the pivotal phase II/III Canadian and European study of
dirucotide (MBP8298) in patients with secondary progressive MS.
The lag analysis included patients from the number one 200 to complete
MAESTRO-01 and assessed the likelihood of the study arrival its basal
endpoint at the end of the trial in MS patients with the target HLA-DR2
and/or HLA-DR4 immune response genes. The DSMB analysis also included a
scheduled review of safety information.
Based on the DSMB decision, Eli Lilly and Company has agreed to provide
the $10 1000000 milestone defrayment to BioMS as region of the terms of the
licensing and collaboration agreement.
"We are very encouraged by the safety board's testimonial," said
Kevin Giese, President and CEO of BioMS Medical. "This positive brushup is
an important milestone for BioMS and our partner, Eli Lilly and Company,
and moves us one footstep closer to our goal of bringing this crucial therapy
to multiple induration patients."
"We are pleased by the results of the meantime analysis and look forward
to last efficacy and safety information from this trial following year," aforementioned Dr. Mark
Freedman, Professor of Neurology at the University of Ottawa and Director
of the MS Research Clinic at the Ottawa Hospital. "If successful, this
novel therapy administered only twice per year, could help a prominent
underserved universe with late stage MS."
About MAESTRO-01
Dirucotide (MBP8298) is being studied in four late-stage clinical trials:
-- MAESTRO-01: A pivotal phase II/III trial for secondary progressive
MS (SPMS) patients in Canada and Europe.
-- MAESTRO-02: An open-label safety extension study to MAESTRO-01.
-- MAESTRO-03: A pivotal phase III trial for SPMS patients in the United
States.
-- MINDSET-01: A phase II trial for relapsing-remitting MS (RRMS)
patients in Europe.
MAESTRO-01 is a multi-center, double-blind, placebo-controlled trial
intentional to value the safety and efficaciousness of dirucotide (MBP8298) in
patients with secondary progressive MS. The study is being conducted at 47
sites crossways Canada and nine countries in Europe and includes 611 patients
being administered either dirucotide (MBP8298) or placebo intravenously
every sextet months for a period of deuce years. The primary clinical endpoint
for the tribulation is defined as a statistically and clinically significant
increase in the time to patterned advance of the disease, as measured by the
Expanded Disability Status Scale (EDSS), in patients with HLA-DR2 and/or
HLA-DR4 immune response genes. Time to disease progression in patients with
other HLA-DR types will be assessed separately as an exploratory arm of the
like study.
About Dirucotide (MBP8298)
Dirucotide (MBP8298) is a synthetic peptide that consists of 17 amino group
acids having a successiveness identical to that of a part of human myelin
introductory protein (MBP). Dirucotide is being developed for the potential
treatment of multiple sclerosis (MS), an autoimmune disease caused by
immune attack against normal components of the central skittish system. The
sequence of dirucotide is associated with the autoimmune process in MS
patients with sure immune response genes (HLA types DR2 and/or DR4); MS
patients having these genes represent 65 to 75 pct of all MS patients.
The drug's apparent mechanism of activeness is the induction or restoration
of immunological leeway with regard to ongoing immune attack as a
result of high doses of peptide periodically delivered intravenously. The
potential benefit of the drug for any case-by-case patient is therefore
expected to be related to the persona this peptide plays in that patient's
immune system. The degree of immunomodulation achieved will depend on the
kinship among the peptide, HLA molecules and T cells.
The results of phase II and long-term follow-up treatment of MS
patients with MBP8298 (dirucotide), published in 2006 in the European
Journal of Neurology (EJN), showed that MBP8298 (dirucotide) safely delayed
medial time to disease progression for basketball team years (versus placebo) in
progressive MS patients with HLA types DR2 and/or DR4. Thus, dirucotide
(MBP8298), if sanctioned, has the potential to be used as a tailored therapy
for patients genetically determined to verbalize the allow HLA
molecules.
About Multiple Sclerosis
Multiple sclerosis (MS) is thought to affect as many as 2.5 million
masses worldwide, including approximately 75,000 in Canada, four hundred,000 in the
United States and more than 500,000 in Europe. It is a disease that affects
more women than hands, with onset typically occurring between 20 and 50 years
of age. MS is caused by hurt to myeline, the protective sheath encompassing
nerve fibers in the central nervous system, which interferes with messages
from the brain to the body. Symptoms of MS may include vision problems,
loss of balance, numbness, difficulty walk and palsy. Approximately
40 percent of all MS patients have the secondary progressive cast of the
disease.
About BioMS Medical Corp.
BioMS Medical is a biotechnology company engaged in the development and
commercialisation of novel therapeutic technologies. BioMS Medical's lead
engineering, dirucotide (MBP8298), is for the intervention of multiple
sclerosis and is organism evaluated in two pivotal phase III clinical trials
for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and
MAESTRO-03 in the United States. It to boot is being evaluated for
relapsing remitting MS patients in a Phase II trial in Europe entitled
MINDSET-01. In December 2007, BioMS entered into a licensing and
development agreement granting Eli Lilly and Company sole worldwide
rights to dirucotide (MBP8298), in exchange for an $87 million upfront
payment, milestone payments and escalating royalties on sales. For farther
information please visit our website at http://www.biomsmedical.com.
This press release may contain modern statements, which
reflect the Company's stream expectation regarding future events. These
forward-looking statements involve risks and uncertainties that may causa
actual results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
innovative statements. Such factors include, but are not limited to,
changing market conditions, the successful and timely completion of
clinical studies, the establishment of corporate alliances, the impact of
competitive products and pricing, new product development, uncertainties
related to the regulative approval process and other risks detailed from
clip to sentence in the Company's ongoing quarterly and annual reporting.
Certain of the assumptions made in preparing innovative statements
include but ar not limited to the following: that MBP8298 will continue to
demonstrate a satisfactory refuge profile in ongoing and future clinical
trials; and that BioMS Medical Corp. will finish the several clinical
trials within the timelines communicated in this release. We undertake no
obligation to publicly update or revise any modern statements,
whether as a result of new data, future events or otherwise.
BioMS Medical Corp.
http://www.biomsmedical.com
More info
MS), a leading developer in the treatment of multiple sclerosis (MS),
proclaimed that the independent Drug Safety Monitoring Board (DSMB) for the
MAESTRO-01 trial has conducted the scheduled interim analysis of efficacy
and safety and has recommended that the tryout continue to completion.
MAESTRO-01 is the pivotal phase II/III Canadian and European study of
dirucotide (MBP8298) in patients with secondary progressive MS.
The lag analysis included patients from the number one 200 to complete
MAESTRO-01 and assessed the likelihood of the study arrival its basal
endpoint at the end of the trial in MS patients with the target HLA-DR2
and/or HLA-DR4 immune response genes. The DSMB analysis also included a
scheduled review of safety information.
Based on the DSMB decision, Eli Lilly and Company has agreed to provide
the $10 1000000 milestone defrayment to BioMS as region of the terms of the
licensing and collaboration agreement.
"We are very encouraged by the safety board's testimonial," said
Kevin Giese, President and CEO of BioMS Medical. "This positive brushup is
an important milestone for BioMS and our partner, Eli Lilly and Company,
and moves us one footstep closer to our goal of bringing this crucial therapy
to multiple induration patients."
"We are pleased by the results of the meantime analysis and look forward
to last efficacy and safety information from this trial following year," aforementioned Dr. Mark
Freedman, Professor of Neurology at the University of Ottawa and Director
of the MS Research Clinic at the Ottawa Hospital. "If successful, this
novel therapy administered only twice per year, could help a prominent
underserved universe with late stage MS."
About MAESTRO-01
Dirucotide (MBP8298) is being studied in four late-stage clinical trials:
-- MAESTRO-01: A pivotal phase II/III trial for secondary progressive
MS (SPMS) patients in Canada and Europe.
-- MAESTRO-02: An open-label safety extension study to MAESTRO-01.
-- MAESTRO-03: A pivotal phase III trial for SPMS patients in the United
States.
-- MINDSET-01: A phase II trial for relapsing-remitting MS (RRMS)
patients in Europe.
MAESTRO-01 is a multi-center, double-blind, placebo-controlled trial
intentional to value the safety and efficaciousness of dirucotide (MBP8298) in
patients with secondary progressive MS. The study is being conducted at 47
sites crossways Canada and nine countries in Europe and includes 611 patients
being administered either dirucotide (MBP8298) or placebo intravenously
every sextet months for a period of deuce years. The primary clinical endpoint
for the tribulation is defined as a statistically and clinically significant
increase in the time to patterned advance of the disease, as measured by the
Expanded Disability Status Scale (EDSS), in patients with HLA-DR2 and/or
HLA-DR4 immune response genes. Time to disease progression in patients with
other HLA-DR types will be assessed separately as an exploratory arm of the
like study.
About Dirucotide (MBP8298)
Dirucotide (MBP8298) is a synthetic peptide that consists of 17 amino group
acids having a successiveness identical to that of a part of human myelin
introductory protein (MBP). Dirucotide is being developed for the potential
treatment of multiple sclerosis (MS), an autoimmune disease caused by
immune attack against normal components of the central skittish system. The
sequence of dirucotide is associated with the autoimmune process in MS
patients with sure immune response genes (HLA types DR2 and/or DR4); MS
patients having these genes represent 65 to 75 pct of all MS patients.
The drug's apparent mechanism of activeness is the induction or restoration
of immunological leeway with regard to ongoing immune attack as a
result of high doses of peptide periodically delivered intravenously. The
potential benefit of the drug for any case-by-case patient is therefore
expected to be related to the persona this peptide plays in that patient's
immune system. The degree of immunomodulation achieved will depend on the
kinship among the peptide, HLA molecules and T cells.
The results of phase II and long-term follow-up treatment of MS
patients with MBP8298 (dirucotide), published in 2006 in the European
Journal of Neurology (EJN), showed that MBP8298 (dirucotide) safely delayed
medial time to disease progression for basketball team years (versus placebo) in
progressive MS patients with HLA types DR2 and/or DR4. Thus, dirucotide
(MBP8298), if sanctioned, has the potential to be used as a tailored therapy
for patients genetically determined to verbalize the allow HLA
molecules.
About Multiple Sclerosis
Multiple sclerosis (MS) is thought to affect as many as 2.5 million
masses worldwide, including approximately 75,000 in Canada, four hundred,000 in the
United States and more than 500,000 in Europe. It is a disease that affects
more women than hands, with onset typically occurring between 20 and 50 years
of age. MS is caused by hurt to myeline, the protective sheath encompassing
nerve fibers in the central nervous system, which interferes with messages
from the brain to the body. Symptoms of MS may include vision problems,
loss of balance, numbness, difficulty walk and palsy. Approximately
40 percent of all MS patients have the secondary progressive cast of the
disease.
About BioMS Medical Corp.
BioMS Medical is a biotechnology company engaged in the development and
commercialisation of novel therapeutic technologies. BioMS Medical's lead
engineering, dirucotide (MBP8298), is for the intervention of multiple
sclerosis and is organism evaluated in two pivotal phase III clinical trials
for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and
MAESTRO-03 in the United States. It to boot is being evaluated for
relapsing remitting MS patients in a Phase II trial in Europe entitled
MINDSET-01. In December 2007, BioMS entered into a licensing and
development agreement granting Eli Lilly and Company sole worldwide
rights to dirucotide (MBP8298), in exchange for an $87 million upfront
payment, milestone payments and escalating royalties on sales. For farther
information please visit our website at http://www.biomsmedical.com.
This press release may contain modern statements, which
reflect the Company's stream expectation regarding future events. These
forward-looking statements involve risks and uncertainties that may causa
actual results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
innovative statements. Such factors include, but are not limited to,
changing market conditions, the successful and timely completion of
clinical studies, the establishment of corporate alliances, the impact of
competitive products and pricing, new product development, uncertainties
related to the regulative approval process and other risks detailed from
clip to sentence in the Company's ongoing quarterly and annual reporting.
Certain of the assumptions made in preparing innovative statements
include but ar not limited to the following: that MBP8298 will continue to
demonstrate a satisfactory refuge profile in ongoing and future clinical
trials; and that BioMS Medical Corp. will finish the several clinical
trials within the timelines communicated in this release. We undertake no
obligation to publicly update or revise any modern statements,
whether as a result of new data, future events or otherwise.
BioMS Medical Corp.
http://www.biomsmedical.com
More info
Thursday, 7 August 2008
Snow Patrol: 'New album is best yet'
Snow Patrol have claimed that their fifth studio album is their "best yet".
Drummer Johnny Quinn told the Belfast Telegraph that their new CD would be coroneted One Hundred Million Suns.
The Dundee rockers, whose last LP was 2006's Eyes Open,
Drummer Johnny Quinn told the Belfast Telegraph that their new CD would be coroneted One Hundred Million Suns.
The Dundee rockers, whose last LP was 2006's Eyes Open,
Friday, 27 June 2008
Diane and David Arkenstone (Enaid)
Artist: Diane and David Arkenstone (Enaid)
Genre(s):
New Age
Discography:
Avalon - A Celtic Legend
Year: 2002
Tracks: 10
Monday, 23 June 2008
Duffy's 'Rockferry' still going strong
Duffy's debut album Rockferry has notched up its 16th week inside the top four.
The LP - this week's number two behind Coldplay's Viva La Vida - has now shifted around 850,000 copies since its release in March. These figures make Rockferry the best selling album of the year to date.
New entries this week come from DJ Darren Styles, who scores a number four debut for Skydivin'; Feeder, at eight with Silent Cry; and American singer-songwriter Sara Bareilles, who nudges into the top ten with Little Voice.
The top ten albums in full:
1. (1) Coldplay: 'Viva La Vida'
2. (3) Duffy: 'Rockferry'
3. (2) Neil Diamond: 'Home Before Dark'
4. (-) Darren Styles: 'Skydivin''
5. (4) Paul Weller: '22 Dreams'
6. (5) The Fratellis: 'Here We Stand'
7. (6) Radiohead: 'The Best Of'
8. (-) Feeder: 'Silent Cry'
9. (-) Sara Bareilles: 'Little Voice'
10. (16) Rihanna: 'Good Girl Gone Bad'
> Click here for this week's singles chart
See Also
The LP - this week's number two behind Coldplay's Viva La Vida - has now shifted around 850,000 copies since its release in March. These figures make Rockferry the best selling album of the year to date.
New entries this week come from DJ Darren Styles, who scores a number four debut for Skydivin'; Feeder, at eight with Silent Cry; and American singer-songwriter Sara Bareilles, who nudges into the top ten with Little Voice.
The top ten albums in full:
1. (1) Coldplay: 'Viva La Vida'
2. (3) Duffy: 'Rockferry'
3. (2) Neil Diamond: 'Home Before Dark'
4. (-) Darren Styles: 'Skydivin''
5. (4) Paul Weller: '22 Dreams'
6. (5) The Fratellis: 'Here We Stand'
7. (6) Radiohead: 'The Best Of'
8. (-) Feeder: 'Silent Cry'
9. (-) Sara Bareilles: 'Little Voice'
10. (16) Rihanna: 'Good Girl Gone Bad'
> Click here for this week's singles chart
See Also
Monday, 16 June 2008
Voight to play villain on Fox's '24' next season
NEW YORK —
See Also
Jon Voight has been cast as the villain on the upcoming season of the Fox drama "24." The seventh season kicks off in January, though Voight will make his first appearance during a two-hour "prequel" episode to air in November, Chris Alexander, a spokesman for the show, said Friday.
The 69-year-old actor's character will resurface in the second half of the regular season, Alexander said.
"I am thrilled and excited about being invited to be part of my favorite show `24,'" Voight said in a statement Friday. "I'm hoping to bring my very best to it."
The actor's previous TV experience includes the classic Western "Gunsmoke," in which he appeared in several episodes during the 1960s.
Voight, also known as the father of Angelina Jolie, won an Academy Award for best actor for the 1978 film "Coming Home," and has been nominated three other times for "Midnight Cowboy," "Runaway Train" and "Ali."
His big-screen credits include "Deliverance," "Mission: Impossible," "Transformers" and the "National Treasure" movies.
---
On the Net:
http://www.fox.com/
See Also
Monday, 9 June 2008
Pete Doherty - Doherty Buys 10000 Moss Painting
British rocker PETE DOHERTY is missing his ex-lover KATE MOSS so much, he spent $10,000 (GBP5,000) on a portrait of her.
The Babyshambles frontman was photographed purchasing the oil painting of the catwalk star from artist Sam Shaker in London.
Doherty commission the work - named the portrait Beauty - when he was still dating Moss last year (07) but never paid the $600 (GBP300) Shaker charged for it.
Shaker was considering auctioning the art for charity - but Doherty claimed it on Tuesday (03Jun08).
See Also
Thursday, 29 May 2008
Steve Mcqueen - Mcqueen Picks Up Cannes Prize For Film Debut
Artist-turned-director STEVE MCQUEEN has been awarded the prestigious Camera d'Or prize at the Cannes Film Festival for his movie debut HUNGER.
Hunger details the final days of Irish Republican Army (IRA) hunger striker Bobby Sands - played by 300 star Michael Fassbender - who died aged 27 in Maze Prison in Belfast, Ireland in 1981.
MCQueen was presented with the award - which honours first-time filmmakers - on Sunday (25May08) by Easy Rider star Dennis Hopper.
See Also
Saturday, 24 May 2008
Joe Claussell
Artist: Joe Claussell
Genre(s):
Dance
House
Electronic
Discography:
![Translate: Sampler [12 VINYL]](http://img.mp3fiesta.com/covers/30/30486/alb_127593_th.jpg)
Translate: Sampler [12 VINYL]
Year: 2006
Tracks: 5
Unchained Rhythums Part.2 Vinyl
Year: 2005
Tracks: 4
Unchained Rhythums Part.1 Vinyl
Year: 2005
Tracks: 4
Language
Year: 2000
Tracks: 8
Music... A Reason To Celebrate (cd2)
Year:
Tracks: 12
Music... A Reason To Celebrate (cd1)
Year:
Tracks: 12
Joe Claussell has long been one of New York City's busiest dance figures, thanks to his make in all areas of the house biotic community: as a extremely respected DJ, manufacturer, remixer, label-head (Ghostlike Life Music and Ibadan), and record-shop owner (Dance Tracks). Spiritual Life has released tracks from a host of New York nu-house teams including Claussell himself, Mateo & Matos, Blaze, Slam Mode, and patronize production mate Jephte Guillaume. And his Sunday clubnight Body & Soul (with mate residents François Kevorkian and Danny Krivit) recreated the vibraharp fostered at the birth of modern dance medicine -- David Mancuso's Loft roger Sessions during the early '70s -- with a varied mix of vivacious music ranging from Milton Nascimento to Masters at Work to Cesario Evora to Kevin Yost to Fela Kuti. In his productions, he's often mirrored that eclecticist mix in of styles, falling in plentifulness of acoustic instruments and rich percussion patterns.
Like Kevorkian, Claussell is a ex-serviceman of the disco geological era, an enthusiastic participator at DJ roger Huntington Sessions from near-legendary figures like Mancuso and Larry Levan. Raised in Brooklyn, he well-read musical variety thanks to the wide-ranging tastes of his 7 brothers. He began working at the New York record fund Dance Tracks in the late '80s, and after forming a partnership with new proprietor Stefan Prescott, turned it into one of the leading vinyl sources in the city. Claussell turned to production with a few remixing credits, and in 1996, launched Spiritual Life Music with the single "Refractory Problems" by Timmy Regisford.
Spiritual Life shortly became the home for productions embracement all forms of groove music from the past tense few decades, as comfortable working through Caribbean folk and salsa rhythms as the expected cryptical theater. (Non surprisingly, the excerpt at the Dance Tracks depot featured the same philosophical system at work.) Tight releases by two of New York's topper producers (Slam Mode with "Edict Mistura," and Blaze with "Directions") increased the label's visibility during the mid-'90s, and Claussell affected into production with majuscule singles by Jephte Guillaume ("The Prayer," "Kanpe") during 1997. He too formed a second label, Ibadan, and released his number 1 proper single, the 1997 Brazilian planetary house physical exertion "Escravos de Joe."
The same vibes fostered on Spiritual Life material likewise constitute a physical exercise at Body & Soul, the Sunday evening club founded by Claussell with François Kevorkian. His number 1 full-length, Unify the Vibe, was released on NiteGrooves in 1999, followed later that year by his proper debut, Speech. A Spiritual Life compiling, Spiritual Life Music, is too useable.
Eddy Arnold Dies At 89
Friday, 23 May 2008
Saw Loser
Artist: Saw Loser
Genre(s):
Rock
Discography:
Long Distance Phone Calls
Year: 2007
Tracks: 11
Taktloss and The Rifleman
Willoughby defends her TV wardrobe
Willoughby defends her TV wardrobe
Television presenter Charles Hardin Holley Willoughby has defended her wardrobe for the reality show 'Dancing on Ice' after criticism from tV audience.
According to reports, members of the world birth complained that the presenter's dresses are overly revelation.
Responding to the complaints on ITV present 'Loose Women', Willoughby said: "It's just the weirdest thing that has of all time happened - like I've been living in someone else's world the last deuce weeks."
"My body dictates that it suits certain things, so I always weary the lapp style of dress. Unfortunately those are the things that fix attention. It would be nice if the publicity was, 'Isn't she good at her job?'."
She as well told The Mirror: "I can't believe the stir it caused. I like to bear feminine clothes and I've had citizenry climax up to me in the street expression how lots they liked it."
Day-Lewis is among the SAG winners
Day-Lewis is among the SAG winners
Daniel Day-Lewis has been named Topper Thespian for his operation in 'There Will Be Blood' at the Screen Actors Guild Awards in the US.
Day-Lewis is Oscar-nominated for his performance and has already won the Golden Globe Award for his portrayal of Daniel Plainview in the Saint Paul Thomas the doubting Apostle Philip Warren Anderson picture show.
Wicklow resident Day-Lewis used his Sag down Awards acceptance lecture to pay tribute to Heath Book of account, world Health Organization was found dead in Newly House of York last calendar week. He described the Aussie actor as an inspiration.
Julie Dame Agatha Mary Clarissa Christie won Best Actress at the CRT screen Actors Club Awards for her performance in 'Away from Her'.
Javier Bardem was named Best Support Doer for his performance in 'No Country for Old Men' patch Crimson Dee was named Best Supporting Actress for her performance in 'American Gangster'.
The Outstanding Performance by a Cast in a Motion Video went to the stars of 'No Country for Old Men'.
The stunt team on 'The Bourn Ultimatum' won the Outstanding Performance by a Stunt Ensemble in a Movement Painting awarding.
For more on the Screen Actors Society Awards, click here.
Dr Phil visits Spears during hospital stay
Sopranos have SAG Awards hat-trick
Sopranos have SAG Awards hat-trick
The stars of 'The Sopranos' were the big winners in the TV categories at the Screen door Actors Gild Awards in the US at the weekend.
James Gandolfini and Edie Falco were named Best Histrion and Actress in a Dramatic event Series respectively spell the cast of 'The Sopranos' won the Outstanding Execution by an Ensemble in a Drama Series laurels.
At that place were two awards for '30 Rock' with stars Alec James Baldwin and Tina Fey named Best Doer and Actress in a Comedy Serial publication respectively.
The upchuck of the US series 'The Office' north Korean won the Outstanding Functioning by an Ensemble in a Comedy Series laurels.
Kevin Franz Joseph Kline won Topper Histrion in a Television Motion picture or Miniseries for 'As You Like It' with Tabby Latifah named Best Actress for 'Life Support'.
The stunt team on '24' north Korean won the award for Outstanding Execution by a Stunt Ensemble in a Telly Series.
For to a greater extent on the Screen door Actors Social club Awards, click here.
Subscribe to:
Posts (Atom)